Scarica l'app Stockscreener
7.10
0.28%
-0.02
Dopo l'orario di chiusura:
7.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.12
Aprire:
$6.96
Volume 24 ore:
3.62M
Relative Volume:
4.10
Capitalizzazione di mercato:
$484.58M
Reddito:
$46.02M
Utile/perdita netta:
$-70.80M
Rapporto P/E:
-2.5177
EPS:
-2.82
Flusso di cassa netto:
$-1.61M
1 W Prestazione:
-4.83%
1M Prestazione:
-20.71%
6M Prestazione:
-12.99%
1 anno Prestazione:
-63.33%
Intervallo 1D:
$6.90
$7.42
Intervallo di 1 settimana:
$6.90
$8.21
Portata 52W:
$6.90
$30.99
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Nome
Eyepoint Pharmaceuticals Inc
Settore
Industria
Telefono
617-926-5000
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Confronta EYPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
7.10 | 484.58M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-22 | Iniziato | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Mizuho | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2021-01-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Ripresa | Laidlaw | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
Mostra tutto
Eyepoint Pharmaceuticals Inc Borsa (EYPT) Ultime notizie
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Franklin Resources Inc. Raises Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
Charles Schwab Investment Management Inc. Raises Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Down 6.4% in November - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of “Buy” from Analysts - Defense World
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 6.4%Here's Why - MarketBeat
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
EyePoint reports inducement grants under NASDAQ listing rule - Yahoo Finance
EyePoint Pharmaceuticals to Present at JP Morgan Healthcare Conference 2025 - StockTitan
EYPT stock touches 52-week low at $7.4 amid market challenges - Investing.com Canada
Short Interest in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Decreases By 6.4% - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Sets New 52-Week LowHere's Why - MarketBeat
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Pharmaceuticals Awards Strategic Stock Options to Expand Leadership Team - StockTitan
When the Price of (EYPT) Talks, People Listen - Stock Traders Daily
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 29% Share Price Plunge Could Signal Some Risk - Simply Wall St
EyePoint begins dosing in second global Phase 3 LUCIA clinical trial of Duravyu for the treatment of wet AMD - Optometry Times
EyePoint Pharmaceuticals (FRA:PV3B) 5-Year Sortino Ratio : 1.27 (As of Dec. 09, 2024) - GuruFocus.com
Point72 Asset Management L.P. Sells 179,451 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
Intech Investment Management LLC Invests $136,000 in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint Pharmaceuticals’ (EYPT) “Buy” Rating Reiterated at HC Wainwright - Defense World
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 7%Still a Buy? - MarketBeat
EyePoint Pharmaceuticals Insiders Sold US$935k Of Shares Suggesting Hesitancy - Simply Wall St
EyePoint Pharmaceuticals (STU:PV3B) PS Ratio : 9.30 (As of Dec. 05, 2024) - GuruFocus.com
EyePoint doses first patient in second Phase 3 LUCIA clinical trial - Yahoo Finance
EyePoint advances wet AMD treatment with new trial By Investing.com - Investing.com Canada
Eyepoint Pharmaceuticals, Inc. Announces First Patient Dosed in Second Global Phase 3 Lucia Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration - Marketscreener.com
Patient Square Capital LP Acquires New Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
EyePoint advances wet AMD treatment with new trial - Investing.com
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration - The Manila Times
EyePoint Launches Landmark Phase 3 Trial for Revolutionary 6-Month Eye Disease Treatment - StockTitan
How To Trade (EYPT) - Stock Traders Daily
EYPT (EyePoint Pharmaceuticals) Median PS Value : $7.51 (As of Dec. 01, 2024) - GuruFocus.com
Connor Clark & Lunn Investment Management Ltd. Sells 71,796 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
EYPT (EyePoint Pharmaceuticals) 3-Year Revenue Growth Rate : -23.90% (As of Sep. 2024) - GuruFocus.com
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
EYPT (EyePoint Pharmaceuticals) Degree of Operating Leverage : 0.73 (As of Sep. 2024) - GuruFocus.com
EYPT (EyePoint Pharmaceuticals) Enterprise Value : $396.54 Mil (As of Nov. 20, 2024) - GuruFocus.com
EyePoint Pharmaceuticals (FRA:PV3B) Enterprise Value : €374.46 Mil (As of Nov. 20, 2024) - GuruFocus.com
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High? - MSN
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register
EyePoint Pharmaceuticals Awards 23,600 Stock Options to New Employees at $9.17 | EYPT Stock News - StockTitan
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 8.5%Here's What Happened - MarketBeat
EyePoint Pharmaceuticals : Announces $16.5 Million Monetization of ILUVIEN Royalty with SWK Holdings Corporation - Marketscreener.com
HC Wainwright Has Pessimistic View of EYPT FY2024 Earnings - MarketBeat
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity - Seeking Alpha
EyePoint price target lowered to $33 from $38 at Baird - Yahoo Finance
(EYPT) Technical Data - Stock Traders Daily
EyePoint Pharmaceuticals Reports $29.4 Million Third Quarter Net Loss - Vision Monday
EyePoint shares retain Outperform as Baird sees upside in DME and wet AMD opportunities - Investing.com
Eyepoint Pharmaceuticals Inc Azioni (EYPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):